The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2008, 181, 7131 -7137
Copyright © 2008 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, H.
Right arrow Articles by Pauza, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, H.
Right arrow Articles by Pauza, C. D.

TNF-{alpha} Is a Positive Regulatory Factor for Human V{gamma}2V{delta}2 T Cells1

Haishan Li, Kun Luo and C. David Pauza2

Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
V{gamma}2V{delta}2 T cells in human peripheral blood recognize phosphoantigen and play important roles in host defense and immunoregulation. The TCR is required for V{gamma}2V{delta}2 T cell responses to phosphoantigen, but less is known about soluble or cell-associated costimulatory molecules. In this study, we show that human V{gamma}2V{delta}2 T cell responses to phosphoantigen, including activation, proliferation, cytokine production, and tumor cell cytotoxicity, require TNF-{alpha} binding to its receptor, with a preference for TNFR2. Because stimulated V{gamma}2V{delta}2 cells also produce TNF-{alpha}, this may be a positive control mechanism to sustain the response. Impaired proliferation in the presence of TNF-{alpha} or TNFR blocking agents was partially rescued by a TLR2 agonist, Pam3Cys. Our studies demonstrate that TNF-{alpha} plays a critical role in regulating human V{gamma}2V{delta}2 T cell immune responses.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The {gamma}{delta} T cells represent a distinct lymphocyte subset characterized by TCR possessing unique structural and Ag-binding properties (1, 2). In human peripheral blood, {gamma}{delta} T cells are 1–10% of total T cells, with the majority (>80%) expressing the V{gamma}2V{delta}2 (also termed V{gamma}9V{delta}2) TCR (hereafter referred to as V{delta}2 T cells) and ~75% of them having the V{gamma}2-J{gamma}1.2 rearrangement (3). V{delta}2 T cells are expanded in vivo in the context of various infectious diseases, such as tuberculosis (4), legionellosis (5), tularemia (6), brucellosis (7), malaria (8), mononucleosis (9), Listeria (10), or Salmonella (11). The stimulating bacterial Ags are low m.w., nonpeptidic compounds termed phosphoantigens (12, 13) that are related to isoprenoid biosynthesis.

In contrast to {alpha}β T cells, {gamma}{delta} cells in humans often lack CD4 or CD8 expression, recognize phosphoantigens in a MHC-unrestricted manner, and do not require Ag processing by professional APCs (12). Similar to NK cells, V{delta}2 T cells express MHC I receptors, including the inhibitory CD94/NKG2 complexes, and killer Ig-like receptors (14, 15) that are involved in tumor recognition and cytolysis. The potently cytotoxic subset in humans is identified by cell surface expression of polysialylated CD56 (16). V{delta}2 T cells display a range of innate effector functions, including the rapid secretion of chemokines MIP-{alpha}, MIP-β, or RANTES (17, 18) and cytokines, including TNF-{alpha} and IFN-{gamma} (19, 20). After phosphoantigen stimulation, V{delta}2 cells express markers of cytotoxicity (21) and contribute to adaptive immunity by providing B cell help and promoting dendritic cell (DC)3 maturation (22, 23). We know that TCR is required for responses to phosphoantigen, but less is known about soluble or cell-associated costimulatory molecules. In this study, we focus on TNF-{alpha} and its role in V{delta}2 cell activation.

TNF-{alpha} was identified originally as a product of lymphocytes or macrophages that caused lysis of tumor cells (24). It is now recognized as a cytokine that is critically required for several biological processes. The pleiotropic actions of TNF-{alpha} include stimulating cell growth and differentiation, promoting inflammation, or inducing cell death mechanisms (25, 26). TNF-{alpha} exerts its effects by binding to cell surface receptor TNFR1 (also known as p55TNFR, p60, CD120a, or TNFRSF1a) or TNFR2 (also known as p75TNFR, p80, CD120b, or TNFRSF1b) (26, 27). Bound TNFRs mediate the assembly of distinct adaptor protein complexes that regulate signaling processes, including kinase or phosphatase activation, lipase stimulation, and protease induction (26).

TNF-{alpha} also has a role in the pathogenesis of inflammatory or immune-mediated diseases, such as rheumatoid arthritis, psoriatic arthritis, and Crohn’s disease (28, 29); therapeutic agents that block TNF-{alpha} activity are in clinical use for these and other conditions (30, 31, 32). Despite impressive efficacy for treating inflammatory diseases, TNF-{alpha} inhibitor therapy carries substantial risk for serious complications, including reactivation of latent tuberculosis (31, 33). Tuberculosis is of particular importance in this study because V{delta}2 cells respond in vitro (34) and in vivo (35) to mycobacteria and may be important for protection against disease.

In previous studies, TNF-{alpha} or its receptors were reported to affect certain aspects of immunity, including DC maturation/recruitment (36), along with {alpha}β T cell priming (37), proliferation (38), recruitment (39), and function (40). Although the mechanisms remain incompletely defined, TNF-{alpha} seems critical for efficient T cell responses (41, 42). In the mouse, the cell response to LPS involves TNF-{alpha} that potently stimulates {gamma}{delta} T cells expressing the p75 TNFR (43). In this work, we studied the effect of TNF-{alpha} on human cells, to define the role for this costimulatory cytokine in V{gamma}2V{delta}2 cell responses to phosphoantigen.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
PBMC and tumor cell lines

Whole blood was obtained from healthy human volunteers who provided written informed consent. Total lymphocytes were separated from heparinized peripheral blood by density gradient centrifugation (Ficoll-Paque; Amersham Biosciences). PBMC and TU167 cells were cultured in RPMI 1640 supplemented with 10% FBS (Life Technologies), 2 mMol/L L-glutamine, and penicillin-streptomycin (100 U/ml and 100 mg/ml, respectively); for Daudi B cells (CCL-213; American Type Culture Collection), 4.5 g/L glucose, 1.5 g/L NaHCO3, 10 mMol/L HEPES, and 1 mMol/L sodium pyruvate were added.

In vitro proliferation assays

PBMC (5 x 105 cells/well) were cultured in 12-well plates with complete medium, 15 µM isopentyl pyrophosphate (IPP; Sigma-Aldrich), and 100 U/ml human rIL-2 (Tecin, Biological Resources Branch, National Institutes of Health). In some experiments, anti-TNF-{alpha} (clone 28401), anti-TNFR1 (clone 16803), anti-TNFR2 (clone 22210), anti-IFN-{gamma} (clone 25723) blocking Abs (R&D Systems), human rTNF-{alpha} (Invitrogen), or the synthetic lipoprotein Pam3Cys-SK4 (Pam3Cys; EMC) were added at varying concentrations. Fresh complete medium and 100 U/ml IL-2 were added every 3 days. The {gamma}{delta} T cell proliferation was measured by staining for CD3 and V{delta}2, then defining the percentage of {gamma}{delta} T cells within the total lymphocyte population at days 0, 4, 7, and 10 by flow cytometry. The V{delta}2 cell numbers were calculated from the total cell count and the subset frequency in lymphocytes.

Purifying V{delta}2+ cells

The V{delta}2+ subsets from fresh PBMC or PBMC expanded with IPP and IL-2 were purified with a MultiSort Kit (Miltenyi Biotec), according to the manufacturer’s instructions. Cells were stained with PE-conjugate V{delta}2 Abs for 10 min on ice. The V{delta}2-PE-labeled cells were washed and incubated with anti-PE MicroBeads for 15 min on ice, then separated in a magnetic field. We achieved 90–98% purity after magnetic bead separation, as measured by flow cytometry.

Cytotoxicity assay

A nonradioactive, fluorometric cytotoxicity assay with calcein-acetoxymethyl (Molecular Probes) was used to measure cytotoxicity against Daudi B cell or TU167 squamous cell tumor lines. Expanded {gamma}{delta} cells (effector cells) were treated with anti-TNFR1 or anti-TNFR2 blocking Abs for 1 h at 37°C and washed to remove the Ab. Daudi B cells or TU167 cells (target cells) were labeled for 15 min with 2 mMol/L calcein-acetoxymethyl at 37°C and then washed once with PBS. Cells were combined at various E:T ratios in 96-well, round-bottom microtiter plates (Corning Glass) and incubated at 37°C in 5% CO2 for 4 h; assays were performed in triplicate. In some cases, neutralizing anti-TNF-{alpha} Abs (5 µg/ml) were added. After incubation, supernatants were transferred to a 96-well flat-bottom microtiter plate, and calcein content was measured using a Wallac Victor2 1420 multichannel counter (l485/535 nm). Percent specific lysis was calculated as follows: (test release – spontaneous release)/(maximum release – spontaneous release) x 100.

Flow cytometry

Unless noted, cells were stained with fluorophore-conjugated mAbs from BD Biosciences. Generally, 3 x 105–5 x 105 cells were washed, resuspended in 50–100 µl of RPMI 1640, and stained with mouse anti-human V{delta}2-PE clone B6, mouse anti-human CD3-FITC clone UCHT1, mouse anti-human CD3-allophycocyanin clone UCHT1, mouse anti-human CD69-PE clone FN50, mouse anti-human CD107a-FITC clone H4A3, and isotype controls, including rabbit anti-mouse IgG1-FITC clone X40, IgG1-PE clone X40, and IgG1-allophycocyanin clone X40. For detecting intracellular IFN-{gamma} or TNF-{alpha}, cells were stained with V{delta}2-PE, then fixed, permeabilized, and incubated for 45 min at 4°C with mouse anti-human IFN-{gamma}-allophycocyanin clone B27 or mouse anti-human TNF-{alpha}-allophycocyanin clone MAb11. Intracellular staining solutions were obtained from the Cytofix/Cytoperm Kit (BD Biosciences). Data for at least 1 x 104 lymphocytes (gated on the basis of forward- and side-scatter profiles) were acquired for each sample on a FACSCalibur flow cytometer (BD Biosciences). All samples were analyzed using FlowJo software (Tree Star). For stimulation before staining, PBMC or V{delta}2 T cells were stimulated with IPP, anti-{gamma}{delta}-TCR Ab (clone B1.1; eBiosciences), Daudi B cells, or TU167 cells for 2–18 h. For intracellular staining, the protein transport inhibitor brefeldin A (BD Biosciences) was added at the beginning of stimulation or 4 h before staining. In some experiments, V{delta}2 T cells were treated with anti-TNFR1 or anti-TNFR2 blocking Abs for 1 h at 37°C before stimulation.

Detecting cytokines by ELISA

Human IFN-{gamma} in culture supernatants was detected with a human IFN-{gamma} ELISA kit (R&D Systems), according to the manufacturer’s directions. Human TNF-{alpha} in culture supernatants was detected with a human TNF-{alpha} ELISA kit (R&D Systems), according to the manufacturer’s directions.

Statistical analysis

Differences among groups were analyzed by Student’s t test. Value of p < 0.05 was considered to be significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
V{delta}2 T cells, but not CD4, CD8, B cells, monocytes, or NK cells, produce TNF-{alpha} in IPP-stimulated PBMC

It was shown before that V{delta}2 T cells produce TNF-{alpha} after IPP stimulation (21, 44). To show whether this is specific to V{delta}2 cells, PBMC were stimulated with IPP (15 µM/ml) in the presence of 10 µg/ml brefeldin A. After 4 h, cell surface markers and intracellular cytokines were stained with anti-V{delta}2, anti-CD3, anti-CD4, anti-CD8, anti-CD14, anti-CD20, anti-CD56, anti-TNF-{alpha}, and isotype-matched controls. For flow cytometry analysis, the cells were gated on V{delta}2+, CD3+CD4+, CD3+CD8+, CD14+ (monocytes), CD20+ (B cells), or CD3–CD56+ (NK cells) cells, and TNF-{alpha} expression was analyzed. The results demonstrated that TNF-{alpha} production in response to IPP was occurring primarily in V{delta}2 T cells and was not substantial among CD3+CD4+, CD3+CD8+, CD14+, CD20+, or CD3–CD56+ cells in these cultures (Fig. 1).


Figure 1
View larger version (18K):
[in this window]
[in a new window]

  		FIGURE 1. V{delta}2 T cells, but not CD4, CD8, B cells, monocytes, or NK cells, produce TNF-{alpha} in IPP-stimulated PBMC. PBMC were stimulated with IPP (15 µM/ml) in the presence of 10 µg/ml brefeldin A. After stimulation for 4 h, the cell surface markers and intracellular cytokine were stained with anti-V{delta}2, anti-CD3, anti-CD4, anti-CD8, anti-CD14, anti-CD20, anti-CD56, anti-TNF-{alpha}, and isotype-matched controls. The expression of TNF-{alpha} was analyzed by flow cytometry. Data are representative of three experiments yielding similar results.

 
The absence of TNF-{alpha} impairs IPP-stimulated V{delta}2 T cell proliferation, activation, and IFN-{gamma} production

To test whether TNF-{alpha} plays an important role in V{delta}2 T cell proliferation, TNF-{alpha} neutralizing Abs were added to IPP/IL-2-treated cultures, and cells were cultured for 10 days. IPP-driven V{delta}2 T cell expansion (both frequency and absolute number) was inhibited significantly by TNF-{alpha} neutralizing Abs in a dose-dependent manner (Fig. 2, A and B).


Figure 2
View larger version (27K):
[in this window]
[in a new window]

  		FIGURE 2. The absence of TNF-{alpha} impairs IPP-stimulated V{delta}2 T cell proliferation, activation, and IFN-{gamma} production. A and B, Anti-TNF-{alpha} blocking Ab at different doses was added to IPP/IL-2-treated cultures, and cells were cultured for 10 days. Both V{delta}2 frequency (A) and absolute number (B) were detected every 3 days. The cultures were set up in triplicate. C, Purified V{delta}2 T cells by magnetic beads from PBMC are shown. D, Purified V{delta}2 T cells stimulated by IPP with or without anti-TNF-{alpha} blocking Ab. After stimulation for 18 h, the level of IFN-{gamma} in cell-free supernatant was detected by ELISA. E, Fresh PBMC were stimulated by IPP with or without anti-TNF-{alpha} blocking Ab, and the activation marker (CD69) expression on V{delta}2 T cells was analyzed by flow cytometry. *, p < 0.01; **, p < 0.001. Data are representative of three experiments yielding similar results.

 
The impact of TNF-{alpha} on cytokine production and activation marker expression was tested next. V{delta}2 T cells were purified (Fig. 2C) and stimulated by IPP with or without anti-TNF-{alpha} neutralizing Abs. After 18 h, the levels of IFN-{gamma} and TNF-{alpha} in cell-free supernatants were detected by ELISA, and expression of the activation marker CD69 on V{delta}2 T cells was analyzed by flow cytometry. The ELISA results revealed low levels of cell-free IFN-{gamma} when V{delta}2 cells were cultured with medium only; IPP stimulation markedly enhanced IFN-{gamma} production. The absence of TNF-{alpha} significantly reduced IFN-{gamma} production (p < 0.01; Fig. 2D). The flow cytometry results showed that IPP induced CD69 expression on V{delta}2 T cells, but activation marker expression was reduced when TNF-{alpha} was blocked (Fig. 2E). There was no effect on proliferation of an isotype-matched Ab against IFN-{gamma} (Fig. 3). Exogenous TNF-{alpha} added to IPP-stimulated PBMC increased V{delta}2 T cell proliferation (Fig. 4) above levels seen normally with IPP stimulation alone.


Figure 3
View larger version (13K):
[in this window]
[in a new window]

  		FIGURE 3. Specific inhibition of V{delta}2 T cell proliferation by TNF neutralizing Abs. Anti-TNF-{alpha} and anti-IFN-{gamma} Ab (5 µg/ml) were added to IPP/IL-2-treated cultures, and cells were cultured for 10 days. Both V{delta}2 frequency (A) and absolute number (B) were measured every 3 days. The cultures were set up in triplicate. Data are representative of three experiments yielding similar results.

 

Figure 4
View larger version (13K):
[in this window]
[in a new window]

  		FIGURE 4. Exogenous TNF-{alpha} increased V{delta}2 T cell proliferation. TNF-{alpha} (50 ng/ml) was added to IPP/IL-2-treated cultures, and cells were cultured for 10 days. Both V{delta}2 frequency (A) and absolute number (B) were measured every 3 days. The cultures were set up in triplicate. Data are representative of three experiments yielding similar results.

 
TNFR2 on V{delta}2 T cells is mainly responsible for enhancing T cell proliferation, activation, and cytokine production

Two distinct receptors, TNFR1 and TNFR2, mediate the multiple effects of TNF-{alpha}. We detected expression of both receptors on V{delta}2 T cells, but TNFR2 was expressed at higher levels than TNFR1 (Fig. 5A). To determine whether blocking either TNFR1 or TNFR2 would affect V{delta}2 cell functions, the receptors were blocked individually with neutralizing Abs and cells were stimulated with IPP, as described above. Blocking both TNFR1 and TNFR2 significantly reduced proliferation (Fig. 5, B and C), CD69 expression (Fig. 5F), IFN-{gamma} (Fig. 5D), and TNF-{alpha} (Fig. 5E) production by V{delta}2 cells in response to IPP. When blocked individually, TNFR2 had a greater impact on V{delta}2 cell responses. These results indicated that TNFR2 was the preferred costimulatory receptor on V{delta}2 T cells similar to what was reported for murine {gamma}{delta} T cells (43).


Figure 5
View larger version (34K):
[in this window]
[in a new window]

  		FIGURE 5. TNFR2 on V{delta}2 T cell is mainly responsible for enhancing T cell proliferation, activation, and cytokine production. A, TNFR1 and TNFR2 expression on V{delta}2 T cells was assessed by flow cytometry. B and C, Anti-TNFR1 or anti-TNFR2 blocking Abs were added to IPP/IL-2-treated cultures at an optimized concentration (5 µg/ml), and cells were cultured for 10 days. Both V{delta}2 frequency (B) and absolute number (C) were detected every 3 days. The cultures were set up in triplicate. D and E, Purified V{delta}2 T cells from primary PBMC or IPP-expanded PBMC were treated with or without anti-TNFR1 or anti-TNFR2 blocking Abs and stimulated by IPP. After stimulation for 18 h, the level of IFN-{gamma} (D) and TNF-{alpha} (E) in cell-free supernatant was detected by ELISA. F, Fresh PBMC were treated with or without anti-TNFR1 or anti-TNFR2 blocking Abs and stimulated by IPP. The activation marker (CD69) expression on V{delta}2 T cells was analyzed by flow cytometry. *, p < 0.01; **, p < 0.001. Data are representative of three experiments yielding similar results.

 
The absence of TNF-{alpha} or TNF-{alpha}/TNFR2 signal impairs V{delta}2 cell cytotoxicity against tumor cells

Using the TNF-{alpha} or TNF-{alpha}/TNFR blocking conditions, we tested the effect on V{delta}2 cell cytotoxicity. Tumor cell lines Daudi and TU167 were used. The results demonstrated that TNF-{alpha} is important for V{delta}2 T cell cytotoxicity. When TNF-{alpha} was blocked during the cytotoxicity assay, specific lysis for both Daudi (Fig. 6A) and TU167 cells (Fig. 6B) was reduced significantly. V{delta}2 T cell cytotoxicity was also impaired when TNFR2 was blocked and the Ab was removed by washing before effector cells were added to targets. These data indicated that TNF-{alpha} and the signal mediated by its receptors on V{delta}2 T cells are important for tumor cytotoxicity.


Figure 6
View larger version (32K):
[in this window]
[in a new window]

  		FIGURE 6. The absence of TNF-{alpha} or TNF-{alpha}/TNFR2 signal impairs V{delta}2 T cell cytotoxicity against tumor cells. A and B, The cytotoxicity function of V{delta}2 T cells against Daudi (A) or TU167 (B) with or without anti-TNF-{alpha}, anti-TNFR1, or anti-TNFR2 blocking Abs was evaluated at different E:T ratio in triplicate. The statistical significance of specific lysis compared with V{delta}2 T cells at E:T = 5:1 was analyzed. *, p < 0.01; **, p < 0.001. Data are representative of three experiments yielding similar results.

 
Tumor cells stimulate TNF-{alpha} production, but not CD107a expression by V{delta}2 T cells

TNF-{alpha}, granzyme, and perforin are important factors for V{delta}2 cell cytotoxicity. We showed before that V{delta}2 T cells are granzyme B and perforin positive (45). In response to TCR ligands (IPP or anti-{gamma}{delta}-TCR Ab), V{delta}2 T cells produce TNF-{alpha} and increase surface expression of CD107a (45). In this study, we show that V{delta}2 cells produce TNF-{alpha} after simulation by Daudi B cells or TU167 cells at a ratio of 1:1. We also know that Daudi cells stimulate V{delta}2 cell proliferation (21), which is consistent with the higher levels of TNF-{alpha}-producing cells compared with TU167, which is a good target, but a poor stimulator. In contrast, tumor cells did not increase the expression of CD107a, irrespective of TNF-{alpha} production (Fig. 7). These data suggest that TNF-{alpha} or other factors may be more important than granzyme release for V{delta}2 cell cytotoxicity.


Figure 7
View larger version (25K):
[in this window]
[in a new window]

  		FIGURE 7. Tumor cells stimulate TNF-{alpha} production, but not CD107a expression on V{delta}2 T cells. IPP-expanded V{delta}2 T cells were stimulated with medium, IPP, anti-{gamma}{delta}-TCR Ab, Daudi, or TU167 cells, respectively. To detect TNF-{alpha}, 10 µg/ml brefeldin A was added. Two hours later, cells were collected and stained with V{delta}2, CD107a, or TNF-{alpha} Abs and analyzed by flow cytometry. Data are representative of three experiments yielding similar results.

 
Pam3Cys, a TLR2 agonist, can rescue V{delta}2 T cell proliferation and IFN-{gamma} production after blocking TNF-{alpha}

Our previous work showed that V{delta}2 cells respond to the TLR2 agonist (Pam3Cys), but require coincident TCR stimulation (45). In this study, we tested whether Pam3Cys can rescue IPP-stimulated V{delta}2 cell proliferation in the absence of TNF-{alpha} signaling. The results showed that Pam3Cys partly increased the proliferative response to IPP (Fig. 8, A and B), indicating that TLR triggering could compensate for the costimulatory function of TNF-{alpha}. Furthermore, to rule out that Pam3Cys might be acting through monocytic or DC in the PBMC culture, we tested this TLR2 agonist on purified V{delta}2 T cell and measured the effect on IFN-{gamma} production. The Pam3Cys rescued IFN-{gamma} production in the presence of blocking Ab against TNF-{alpha} (Fig. 8C), showing that signaling through TLR2 partly substituted for TNF-{alpha} in V{delta}2 T cell activation.


Figure 8
View larger version (15K):
[in this window]
[in a new window]

  		FIGURE 8. Pam3Cys, a TLR2 agonist, can rescue V{delta}2 T cell proliferation and IFN-{gamma} production after blocking TNF-{alpha}. A and B, Anti-TNF-{alpha} blocking Ab (5 µg/ml) or Pam3Cys (10 µg/ml) was added to IPP/IL-2-treated cultures, and cells were cultured for 10 days. Both V{delta}2 frequency (A) and absolute number (B) were detected every 3 days. The cultures were set up in triplicate. C, Purified V{delta}2 T cells from primary PBMC or IPP-expanded PBMC were treated with or without anti-TNF-{alpha} blocking Abs or Pam3Cys and stimulated by IPP. After stimulation for 18 h, the level of IFN-{gamma} in cell-free supernatant was detected by ELISA. Data are representative of three experiments yielding similar results.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
Human V{delta}2 T cells play important roles in host defense, but have Ag recognition and immunoregulation mechanisms distinct from conventional T cells. In the present study, we focused on the impact of TNF-{alpha} on V{delta}2 T cell function. The V{delta}2 T cell responses to Ag stimulation, including activation, proliferation, cytokine production, and tumor cell cytotoxicity, were impaired significantly when TNF-{alpha} or its receptor was blocked. It is well known that V{delta}2 T cells produce TNF-{alpha} after TCR stimulation; in this study, we showed that V{delta}2 T cells are the major source of TNF-{alpha} in IPP-stimulated PBMC. Now we show that TNF-{alpha} is a positive regulator of human V{delta}2 T cells similar to what was reported for murine {gamma}{delta} T cells (43). Another cytokine, IL-2, is also required for IPP-driven V{delta}2 T cells expansion in vitro (21, 46) and in vivo (47), but is not produced by V{delta}2 cells and must be supplied exogenously. Stimulated V{delta}2 cells are the primary source of TNF-{alpha} in our PBMC cultures, so an exogenous source is not required. The costimulatory signal is important for TCR-dependent activation and cytokine production by V{delta}2 T cells.

The TNF-{alpha} signal is mediated by binding to TNFRs. TNFRs comprise a superfamily of proteins with at least 41 members that are characterized by sequence homology within the extracellular domains. This group includes TNFRs, Fas, CD40, the low-affinity nerve growth factor receptor, TRAIL receptors, RANK, and other death and decoy receptors (48). TNF ligand achieves all its different cellular and pathological effects by binding to TNFR1 and TNFR2 (26). Our studies demonstrated that both TNFR1 and TNFR2 were expressed on V{delta}2 T cells, but TNFR2 was expressed at a higher level. Further studies using neutralizing Abs showed that TNFR2 is mainly responsible for mediating TNF-{alpha} effects on V{delta}2 T cells. Although this can be explained partly by the relative expression levels, it might be due to the different characteristics and cellular consequences of these two different TNFRs and their signaling pathways (26).

The TNF-{alpha}/TNFR signal might be substituted by other costimulatory factors that induce similar signaling pathways. Published studies demonstrated that TNF-{alpha} binding to its receptors triggers a series of intracellular events that ultimately result in the activation of two major transcription factors, NF-{kappa}B and c-Jun (26), which are important for cell growth and activation. Alternately, TLR signaling involves a family of five adaptor proteins that couple to downstream protein kinases that ultimately lead to activation of NF-{kappa}B and members of the IFN-regulatory factor family. We know that V{delta}2 T cells respond to TLR2 agonist (Pam3Cys) with coincident TCR stimulation (45), and we showed in this study that Pam3Cys partly rescued V{delta}2 T cell proliferation in the absence of TNF-{alpha}. This suggests the importance of NF-{kappa}B signaling pathway in initiating V{delta}2 T cell proliferation.

Blocking TNF-{alpha} or its receptors significantly impaired V{delta}2 T cell cytotoxicity against tumor cells. This may be due to the combined effects of blocking cell proliferation and reducing production of TNF-{alpha} itself. This shows that TNF-{alpha} signaling is required for effector functions, including high-level TNF-{alpha} release.

Our studies may have clinical significance for anti-TNF-{alpha} therapy. Recognition of the central role for TNF-{alpha} in the pathophysiology of inflammation led to the development of TNF-{alpha} inhibitors that have revolutionized the therapeutic approaches to autoimmune and inflammatory diseases (31). The initial clinical experience with TNF-{alpha} inhibitors demonstrated impressive efficacy against rheumatoid arthritis, but carried a risk for tuberculosis (31, 33). Tuberculosis appeared commonly within the first few months of use, frequently was disseminated or atypical in presentation, and resulted in high death rates. These cases were believed due, in most cases, to reactivation of latent mycobacterial infection (32).

Several lines of evidence suggest that V{delta}2 T cells are involved in the protective immune response against tuberculosis. The V{delta}2 cells expand in response to nonpeptidic Ags from mycobacterium (34, 49), and they accumulate in bacillus Calmette-Guerin-vaccinated and purified protein derivative skin test-positive individuals with latent tuberculosis infection (35, 50). V{delta}2 T cell effector functions, such as TNF-{alpha} and IFN-{gamma} secretion, cytotoxicity, and a capacity to reduce the viability of extracellular and intracellular mycobacteria, have all been associated with protective immunity (16, 51, 52). We hypothesize that the impairment of V{delta}2 T cells might be an important reason for the high risk of tuberculosis in recipients of anti-TNF-{alpha} therapy. It may be important to consider supportive therapies, including agonists for TLR2 or similar agents, to overcome the block to TNF-{alpha} signaling. These adjunctive agents may restore the protective effects of V{delta}2 T cells against tuberculosis and other opportunistic infections that arise when TNF-{alpha} signaling is interrupted.


   Acknowledgments
 
We thank Cheryl Armstrong for technical assistance. We are grateful to Cristiana Cairo and Jean-Saville Cummings for critical reading of the manuscript.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by Public Health Service Grant AI077059 (to C.D.P.). Back

2 Address correspondence and reprint requests to Dr. C. David Pauza, 725 West Lombard Street, Room N546, Baltimore, MD 21201. E-mail address: cdpauza{at}ihv.umaryland.edu Back

3 Abbreviations used in this paper: DC, dendritic cell; IPP, isopentyl pyrophosphate. Back

Received for publication July 2, 2008. Accepted for publication September 12, 2008.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Shin, S., R. El-Diwany, S. Schaffert, E. J. Adams, K. C. Garcia, P. Pereira, Y. H. Chien. 2005. Antigen recognition determinants of {gamma}{delta} T cell receptors. Science 308: 252-255. [Abstract/Free Full Text]
  2. Carding, S. R., P. J. Egan. 2002. Gamma{delta} T cells: functional plasticity and heterogeneity. Nat. Rev. Immunol. 2: 336-345. [Medline]
  3. Evans, P. S., P. J. Enders, C. Yin, T. J. Ruckwardt, M. Malkovsky, C. D. Pauza. 2001. In vitro stimulation with a non-peptidic alkylphosphate expands cells expressing V{gamma}2-J{gamma}1.2/V{delta}2 T-cell receptors. Immunology 104: 19-27. [Medline]
  4. Balbi, B., M. T. Valle, S. Oddera, D. Giunti, F. Manca, G. A. Rossi, L. Allegra. 1993. T-lymphocytes with {gamma}{delta}+ V{delta}2+ antigen receptors are present in increased proportions in a fraction of patients with tuberculosis or with sarcoidosis. Am. Rev. Respir. Dis. 148: 1685-1690. [Medline]
  5. Kroca, M., A. Johansson, A. Sjostedt, A. Tarnvik. 2001. V{gamma}9V{delta}2 T cells in human legionellosis. Clin. Diagn. Lab. Immunol. 8: 949-954. [Medline]
  6. Poquet, Y., M. Kroca, F. Halary, S. Stenmark, M. A. Peyrat, M. Bonneville, J. J. Fournie, A. Sjostedt. 1998. Expansion of V{gamma}9V{delta}2 T cells is triggered by Francisella tularensis-derived phosphoantigens in tularemia but not after tularemia vaccination. Infect. Immun. 66: 2107-2114. [Abstract/Free Full Text]
  7. Bertotto, A., R. Gerli, F. Spinozzi, C. Muscat, F. Scalise, G. Castellucci, M. Sposito, F. Candio, R. Vaccaro. 1993. Lymphocytes bearing the {gamma}{delta} T cell receptor in acute Brucella melitensis infection. Eur. J. Immunol. 23: 1177-1180. [Medline]
  8. Roussilhon, C., M. Agrapart, P. Guglielmi, A. Bensussan, P. Brasseur, J. J. Ballet. 1994. Human TCR {gamma}{delta}+ lymphocyte response on primary exposure to Plasmodium falciparum. Clin. Exp. Immunol. 95: 91-97. [Medline]
  9. Hassan, J., C. Feighery, B. Bresnihan, A. Whelan. 1991. Elevated T cell receptor {gamma}{delta}+ T cells in patients with infectious mononucleosis. Br. J. Haematol. 77: 255-256. [Medline]
  10. Jouen-Beades, F., E. Paris, C. Dieulois, J. F. Lemeland, V. Barre-Dezelus, S. Marret, G. Humbert, J. Leroy, F. Tron. 1997. In vivo and in vitro activation and expansion of {gamma}{delta} T cells during Listeria monocytogenes infection in humans. Infect. Immun. 65: 4267-4272. [Abstract]
  11. Hara, T., Y. Mizuno, K. Takaki, H. Takada, H. Akeda, T. Aoki, M. Nagata, K. Ueda, G. Matsuzaki, Y. Yoshikai, et al 1992. Predominant activation and expansion of V{gamma}9-bearing {gamma}{delta} T cells in vivo as well as in vitro in Salmonella infection. J. Clin. Invest. 90: 204-210. [Medline]
  12. Constant, P., F. Davodeau, M. A. Peyrat, Y. Poquet, G. Puzo, M. Bonneville, J. J. Fournie. 1994. Stimulation of human {gamma}{delta} T cells by nonpeptidic mycobacterial ligands. Science 264: 267-270. [Abstract/Free Full Text]
  13. Tanaka, Y., C. T. Morita, E. Nieves, M. B. Brenner, B. R. Bloom. 1995. Natural and synthetic non-peptide antigens recognized by human {gamma}{delta} T cells. Nature 375: 155-158. [Medline]
  14. Poccia, F., B. Cipriani, S. Vendetti, V. Colizzi, Y. Poquet, L. Battistini, M. Lopez-Botet, J. J. Fournie, M. L. Gougeon. 1997. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V{gamma} 9V{delta}2 T lymphocytes. J. Immunol. 159: 6009-6017. [Abstract]
  15. Battistini, L., G. Borsellino, G. Sawicki, F. Poccia, M. Salvetti, G. Ristori, C. F. Brosnan. 1997. Phenotypic and cytokine analysis of human peripheral blood {gamma}{delta} T cells expressing NK cell receptors. J. Immunol. 159: 3723-3730. [Abstract]
  16. Alexander, A. A., A. Maniar, J. S. Cummings, A. M. Hebbeler, D. H. Schulze, B. R. Gastman, C. D. Pauza, S. E. Strome, A. I. Chapoval. 2008. Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin. Cancer Res. 14: 4232-4240. [Abstract/Free Full Text]
  17. Poccia, F., L. Battistini, B. Cipriani, G. Mancino, F. Martini, M. L. Gougeon, V. Colizzi. 1999. Phosphoantigen-reactive V{gamma}9V{delta}2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines. J. Infect. Dis. 180: 858-861. [Medline]
  18. Tikhonov, I., C. O. Deetz, R. Paca, S. Berg, V. Lukyanenko, J. K. Lim, C. D. Pauza. 2006. Human V{gamma}2V{delta}2 T cells contain cytoplasmic RANTES. Int. Immunol. 18: 1243-1251. [Abstract/Free Full Text]
  19. Subauste, C. S., J. Y. Chung, D. Do, A. H. Koniaris, C. A. Hunter, J. G. Montoya, S. Porcelli, J. S. Remington. 1995. Preferential activation and expansion of human peripheral blood {gamma}{delta} T cells in response to Toxoplasma gondii in vitro and their cytokine production and cytotoxic activity against T. gondii-infected cells. J. Clin. Invest. 96: 610-619. [Medline]
  20. Wang, L., H. Das, A. Kamath, J. F. Bukowski. 2001. Human V{gamma}2V{delta}2 T cells produce IFN-{gamma} and TNF-{alpha} with an on/off/on cycling pattern in response to live bacterial products. J. Immunol. 167: 6195-6201. [Abstract/Free Full Text]
  21. Li, H., C. O. Deetz, J. C. Zapata, C. Cairo, A. M. Hebbeler, N. Propp, M. S. Salvato, Y. Shao, C. D. Pauza. 2007. Vaccinia virus inhibits T cell receptor-dependent responses by human {gamma}{delta} T cells. J. Infect. Dis. 195: 37-45. [Medline]
  22. Brandes, M., K. Willimann, A. B. Lang, K. H. Nam, C. Jin, M. B. Brenner, C. T. Morita, B. Moser. 2003. Flexible migration program regulates {gamma}{delta} T-cell involvement in humoral immunity. Blood 102: 3693-3701. [Abstract/Free Full Text]
  23. Leslie, D. S., M. S. Vincent, F. M. Spada, H. Das, M. Sugita, C. T. Morita, M. B. Brenner. 2002. CD1-mediated {gamma}/{delta} T cell maturation of dendritic cells. J. Exp. Med. 196: 1575-1584. [Abstract/Free Full Text]
  24. Carswell, E. A., L. J. Old, R. L. Kassel, S. Green, N. Fiore, B. Williamson. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72: 3666-3670. [Abstract/Free Full Text]
  25. Calzascia, T., M. Pellegrini, H. Hall, L. Sabbagh, N. Ono, A. R. Elford, T. W. Mak, P. S. Ohashi. 2007. TNF-{alpha} is critical for antitumor but not antiviral T cell immunity in mice. J. Clin. Invest. 117: 3833-3845. [Medline]
  26. MacEwan, D. J.. 2002. TNF receptor subtype signalling: differences and cellular consequences. Cell. Signal. 14: 477-492. [Medline]
  27. Wajant, H., K. Pfizenmaier, P. Scheurich. 2003. Tumor necrosis factor signaling. Cell Death Differ. 10: 45-65. [Medline]
  28. McDevitt, H., S. Munson, R. Ettinger, A. Wu. 2002. Multiple roles for tumor necrosis factor-{alpha} and lymphotoxin {alpha}/β in immunity and autoimmunity. Arthritis Res. 4: (Suppl. 3):S141-S152. [Medline]
  29. Kollias, G.. 2005. TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin. Arthritis Rheum. 34: 3-6. [Medline]
  30. Deng, G. M., L. Zheng, F. K. Chan, M. Lenardo. 2005. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat. Med. 11: 1066-1072. [Medline]
  31. Winthrop, K. L., S. Yamashita, S. E. Beekmann, P. M. Polgreen. 2008. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin. Infect. Dis. 46: 1738-1740. [Medline]
  32. Iseman, M. D., A. Fischer. 2008. Tumor necrosis factor-{alpha} at the intersection of mycobacterial immunity and pathogenesis: an important new address in medicine. Clin. Infect. Dis. 46: 1741-1742. [Medline]
  33. Ellerin, T., R. H. Rubin, M. E. Weinblatt. 2003. Infections and anti-tumor necrosis factor {alpha} therapy. Arthritis Rheum. 48: 3013-3022. [Medline]
  34. Havlir, D. V., J. J. Ellner, K. A. Chervenak, W. H. Boom. 1991. Selective expansion of human {gamma}{delta} T cells by monocytes infected with live Mycobacterium tuberculosis. J. Clin. Invest. 87: 729-733. [Medline]
  35. Li, B., M. D. Rossman, T. Imir, A. F. Oner-Eyuboglu, C. W. Lee, R. Biancaniello, S. R. Carding. 1996. Disease-specific changes in {gamma}{delta} T cell repertoire and function in patients with pulmonary tuberculosis. J. Immunol. 157: 4222-4229. [Abstract]
  36. Trevejo, J. M., M. W. Marino, N. Philpott, R. Josien, E. C. Richards, K. B. Elkon, E. Falck-Pedersen. 2001. TNF-{alpha}-dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection. Proc. Natl. Acad. Sci. USA 98: 12162-12167. [Abstract/Free Full Text]
  37. Bromberg, J. S., K. D. Chavin, S. L. Kunkel. 1992. Anti-tumor necrosis factor antibodies suppress cell-mediated immunity in vivo. J. Immunol. 148: 3412-3417. [Abstract]
  38. Boyman, O., H. P. Hefti, C. Conrad, B. J. Nickoloff, M. Suter, F. O. Nestle. 2004. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-{alpha}. J. Exp. Med. 199: 731-736. [Abstract/Free Full Text]
  39. Sata, M., K. Walsh. 1998. TNF{alpha} regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat. Med. 4: 415-420. [Medline]
  40. Kafrouni, M. I., G. R. Brown, D. L. Thiele. 2003. The role of TNF-TNFR2 interactions in generation of CTL responses and clearance of hepatic adenovirus infection. J. Leukocyte Biol. 74: 564-571. [Abstract/Free Full Text]
  41. Rothe, J., W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Steinmetz, H. Bluethmann. 1993. Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364: 798-802. [Medline]
  42. Marino, M. W., A. Dunn, D. Grail, M. Inglese, Y. Noguchi, E. Richards, A. Jungbluth, H. Wada, M. Moore, B. Williamson, et al 1997. Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. USA 94: 8093-8098. [Abstract/Free Full Text]
  43. Lahn, M., H. Kalataradi, P. Mittelstadt, E. Pflum, M. Vollmer, C. Cady, A. Mukasa, A. T. Vella, D. Ikle, R. Harbeck, et al 1998. Early preferential stimulation of {gamma}{delta} T cells by TNF-{alpha}. J. Immunol. 160: 5221-5230. [Abstract/Free Full Text]
  44. Li, H., H. Peng, P. Ma, Y. Ruan, B. Su, X. Ding, C. Xu, C. D. Pauza, Y. Shao. 2008. Association between V{gamma}2V{delta}2 T cells and disease progression after infection with closely related strains of HIV in China. Clin. Infect. Dis. 46: 1466-1472. [Medline]
  45. Deetz, C. O., A. M. Hebbeler, N. A. Propp, C. Cairo, I. Tikhonov, C. D. Pauza. 2006. {gamma} Interferon secretion by human V{gamma}2V{delta}2 T cells after stimulation with antibody against the T-cell receptor plus the Toll-like receptor 2 agonist Pam3Cys. Infect. Immun. 74: 4505-4511. [Abstract/Free Full Text]
  46. Hebbeler, A. M., C. Cairo, J. S. Cummings, C. D. Pauza. 2007. Individual V{gamma}2-J{gamma}1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens. Cancer Immunol. Immunother. 56: 819-829. [Medline]
  47. Sicard, H., S. Ingoure, B. Luciani, C. Serraz, J. J. Fournie, M. Bonneville, J. Tiollier, F. Romagne. 2005. In vivo immunomanipulation of V{gamma}9V{delta}2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J. Immunol. 175: 5471-5480. [Abstract/Free Full Text]
  48. Inoue, J., T. Ishida, N. Tsukamoto, N. Kobayashi, A. Naito, S. Azuma, T. Yamamoto. 2000. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp. Cell Res. 254: 14-24. [Medline]
  49. Kabelitz, D., A. Bender, S. Schondelmaier, B. Schoel, S. H. Kaufmann. 1990. A large fraction of human peripheral blood {gamma}/{delta}+ T cells is activated by Mycobacterium tuberculosis but not by its 65-kD heat shock protein. J. Exp. Med. 171: 667-679. [Abstract/Free Full Text]
  50. Hoft, D. F., R. M. Brown, S. T. Roodman. 1998. Bacille Calmette-Guerin vaccination enhances human {gamma}{delta} T cell responsiveness to mycobacteria suggestive of a memory-like phenotype. J. Immunol. 161: 1045-1054. [Abstract/Free Full Text]
  51. Thoma-Uszynski, S., S. Stenger, R. L. Modlin. 2000. CTL-mediated killing of intracellular Mycobacterium tuberculosis is independent of target cell nuclear apoptosis. J. Immunol. 165: 5773-5779. [Abstract/Free Full Text]
  52. Dieli, F., M. Troye-Blomberg, J. Ivanyi, J. J. Fournie, A. M. Krensky, M. Bonneville, M. A. Peyrat, N. Caccamo, G. Sireci, A. Salerno. 2001. Granulysin-dependent killing of intracellular and extracellular Mycobacterium tuberculosis by V{gamma}9/V{delta}2 T lymphocytes. J. Infect. Dis. 184: 1082-1085. [Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, H.
Right arrow Articles by Pauza, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, H.
Right arrow Articles by Pauza, C. D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS